Abstract
Ribosome-Inactivating Proteins (RIPs) are enzymes that trigger the catalytic inactivation of ribosomes and other substrates. They are present in a large number of plants and have been found also in fungi, algae and bacteria. RIPs are currently classified as type 1, those formed by a single polypeptide chain with the enzymatic activity, and type 2, those formed by 2 types of chains, i.e. A chains equivalent to a type 1 RIPs and B chains with lectin activity. Type 2 RIPs usually contain the formulae A-B, (A-B)2 and less frequent (A-B)4 and polymeric forms of type 2 RIPs lectins. RIPs are broadly distributed in plants, and are present also in fungi, bacteria, at least in one alga; recently RIP-type activity has been described in mammalian tissues. The highest number of RIPs has been found in Caryophyllaceae, Sambucaceae, Cucurbitaceae, Euphorbiaceae, Phytolaccaceae and Poaceae. However there are no systematic screening studies to allow generalisations about occurrence. The most known activity of RIPs is the translational inhibitory activity, which seems a consequence of a N-glycosidase on the 28 S rRNA of the eukaryotic ribosome that triggers the split of the A4324 (or an equivalent base in other ribosomes), which is key for translation. This activity seems to be part of a general adenine polynucleotide glycosylase able to act on several substrates other than ribosomes, such as tRNA, mRNA, viral RNA and DNA. Other enzymatic activities found in RIPs are lipase, chitinase and superoxide dismutase. RIPs are phylogenetically related. In general RIPs from close families share good amino acid homologies. Type 1 RIPs and the A chains of type 2 RIPs from Magnoliopsida (dicotyledons) are closely related. RIPs from Liliopsida (monocotyledons) are at the same time closely related and distant from Magnoliopsida. Concerning the biological roles played by RIPs there are several hypotheses, but the current belief is that they could play significant roles in the antipathogenic (viruses and fungi), stress and senescence responses. In addition, roles as antifeedant and storage proteins have been also proposed. Future research will approach the potential biological roles played by RIPs and their use as toxic effectors in the construction of immunotoxins and conjugates for target therapy.
Keywords: ribosome-inactivating proteins, catalytic inactivation, type 2 rips lectins, caryophyllaceae
Mini-Reviews in Medicinal Chemistry
Title: Description, Distribution, Activity and Phylogenetic Relationship of Ribosome-Inactivating Proteins in Plants, Fungi and Bacteria
Volume: 4 Issue: 5
Author(s): Tomas Girbes, Jose Miguel Ferreras, Francisco Javier Arias and Fiorenzo Stirpe
Affiliation:
Keywords: ribosome-inactivating proteins, catalytic inactivation, type 2 rips lectins, caryophyllaceae
Abstract: Ribosome-Inactivating Proteins (RIPs) are enzymes that trigger the catalytic inactivation of ribosomes and other substrates. They are present in a large number of plants and have been found also in fungi, algae and bacteria. RIPs are currently classified as type 1, those formed by a single polypeptide chain with the enzymatic activity, and type 2, those formed by 2 types of chains, i.e. A chains equivalent to a type 1 RIPs and B chains with lectin activity. Type 2 RIPs usually contain the formulae A-B, (A-B)2 and less frequent (A-B)4 and polymeric forms of type 2 RIPs lectins. RIPs are broadly distributed in plants, and are present also in fungi, bacteria, at least in one alga; recently RIP-type activity has been described in mammalian tissues. The highest number of RIPs has been found in Caryophyllaceae, Sambucaceae, Cucurbitaceae, Euphorbiaceae, Phytolaccaceae and Poaceae. However there are no systematic screening studies to allow generalisations about occurrence. The most known activity of RIPs is the translational inhibitory activity, which seems a consequence of a N-glycosidase on the 28 S rRNA of the eukaryotic ribosome that triggers the split of the A4324 (or an equivalent base in other ribosomes), which is key for translation. This activity seems to be part of a general adenine polynucleotide glycosylase able to act on several substrates other than ribosomes, such as tRNA, mRNA, viral RNA and DNA. Other enzymatic activities found in RIPs are lipase, chitinase and superoxide dismutase. RIPs are phylogenetically related. In general RIPs from close families share good amino acid homologies. Type 1 RIPs and the A chains of type 2 RIPs from Magnoliopsida (dicotyledons) are closely related. RIPs from Liliopsida (monocotyledons) are at the same time closely related and distant from Magnoliopsida. Concerning the biological roles played by RIPs there are several hypotheses, but the current belief is that they could play significant roles in the antipathogenic (viruses and fungi), stress and senescence responses. In addition, roles as antifeedant and storage proteins have been also proposed. Future research will approach the potential biological roles played by RIPs and their use as toxic effectors in the construction of immunotoxins and conjugates for target therapy.
Export Options
About this article
Cite this article as:
Girbes Tomas, Ferreras Miguel Jose, Arias Javier Francisco and Stirpe Fiorenzo, Description, Distribution, Activity and Phylogenetic Relationship of Ribosome-Inactivating Proteins in Plants, Fungi and Bacteria, Mini-Reviews in Medicinal Chemistry 2004; 4 (5) . https://dx.doi.org/10.2174/1389557043403891
DOI https://dx.doi.org/10.2174/1389557043403891 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Interactive Effect of Cigarette Smoking and Gene Variants for Predisposing to Cardiovascular Disease
Current Pharmaceutical Design Erlotinib in Non-Small Cell Lung Cancer: From a thought to Necessity
Clinical Cancer Drugs Diaryl Urea: A Privileged Structure in Anticancer Agents
Current Medicinal Chemistry Harnessing Polypharmacology with Computer-Aided Drug Design and Systems Biology
Current Pharmaceutical Design Peroxisome Proliferator Activated Receptor-Gamma Ligands as Potent Antineoplastic Agents
Current Medicinal Chemistry - Anti-Cancer Agents ACKNOWLEDGEMENTS TO CONTRIBUTORS
Recent Patents on Anti-Cancer Drug Discovery Plant and Animal Steroids a New Hope to Search for Antiviral Agents
Current Medicinal Chemistry Cross-Talk Between the Androgen Receptor and the Phosphatidylinositol 3-Kinase/Akt Pathway in Prostate Cancer
Current Cancer Drug Targets Epigenetic Modulation: A Promising Avenue to Advance Hematopoietic Stem Cell-Based Therapy for Severe Autoimmune Disorders
Epigenetic Diagnosis & Therapy (Discontinued) RNA as A Target for Host Defense and Anti-HIV Drugs
Current Drug Targets Targeting Aurora Kinases: A Novel Approach to Curb the Growth & Chemoresistance of Androgen Refractory Prostate Cancer
Current Cancer Drug Targets Inflammation and Pancreatic Cancer: Recent Development with Focusing on Potential New Drug Targets
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Protein-Protein Interactions: Lessons Learned
Current Medicinal Chemistry - Anti-Cancer Agents Chitinases: Biomarkers for Human Diseases
Protein & Peptide Letters Nanoembedded Microparticles for Stabilization and Delivery of Drug-Loaded Nanoparticles
Current Pharmaceutical Design Patent Selections
Recent Patents on Anti-Cancer Drug Discovery Information Theoretic Entropy for Molecular Classification: Oxadiazolamines as Potential Therapeutic Agents
Current Computer-Aided Drug Design Selective VEGFR Inhibitors for Anticancer Therapeutics in Clinical Use and Clinical Trials
Current Pharmaceutical Design The Potential of 11C-acetate PET for Monitoring the Fatty Acid Synthesis Pathway in Tumors
Current Pharmaceutical Biotechnology Molecularly Engineered Polymer-Based Systems in Drug Delivery and Regenerative Medicine
Current Pharmaceutical Design